Repeated dosing with donepezil does not affect the safety, tolerability or pharmacokinetics of single-dose thioridazine in young volunteers

British Journal of Clinical Pharmacology, Supplement

Volumn 58, Issue 1, 2004, Pages 34-40

  Ravic, Miroslav ^a   Warrington, Steve ^b   Boyce, Malcolm ^b   Dunn, Kate ^b   Johnston, Atholl ^c  

^a EISAI CO LTD   (Japan)

^b CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; Donepezil; Drug drug interactions; Pharmacokinetics; Thioridazine

Indexed keywords

DONEPEZIL; THIORIDAZINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; SYNCOPE; ALZHEIMER DISEASE; CLINICAL ARTICLE; DRUG DOSE REGIMEN; DRUG MONITORING; DRUG RESPONSE; SINGLE DRUG DOSE;

EID: 8844239111     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.01800.x     Document Type: Article

References (27)

1. Katzman R, Saitoh T. Advances in Alzheimer's disease. FASEB J 1991; 5: 278-86.
2. Becker RE. Therapy of the cognitive deficit in Alzheimer's disease: the cholinergic system. In Cholinergic Basis for Alzheimer Therapy, eds Becker R, Giacobini E. Boston: Birkhäuser, 1991: 1-30.
3. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-45.
4. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL, Friedhoff LT. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-44.
5. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P; Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-95.
6. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD; "312" Study Group. A 1-year placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481-8.
7. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E; Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613-20.
8. Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil following single oral doses. Br J Clin Pharmacol 1998; 46(Suppl. 1): 1-6.
9. 14C-donepezil in healthy volunteers: a single-dose study. Br J Clin Pharmacol 1998; 46(Suppl. 1): 19-24.
10. Wright N. Removal of thioridazine from primary care formulary will result in prescribing vacuum. BMJ 2001; 323: 695.
11. Kirchner V, Kelly CA, Harvey RJ. Thioridazine for dementia. Cochrane Database Syst Rev 2001: CD000464.
12. Committee on Safety of Medicines. Thioridazine: Restricted Indications and New Warning on Cardiotoxicity. London: CSM, 2000.
13. Davies SJ, Cooke LB, Moore AG, Potokar J. Discontinuation of thioridazine in patients with learning disabilities: balancing cardiovascular toxicity with adverse consequences of changing drugs. BMJ 2002; 324: 1519-21.
14. Otani K, Aoshima T. Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit 2000; 22: 118-21.
15. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355: 1048-52.
16. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001; 58: 1161-7.
17. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774-82.
18. Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SH. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 1996; 60: 543-53.
19. Lee JW, Rogers SL, Freidhoff LT, Stiles MR, Cooper NM. Validation and application of an HPLC method for the determination of 1-benzyl-4-[(5,6- dimethoxy-1-indanon)-2-yl] methyl piperidine (E2020) in human plasma. Pharm Res 1992; 9: S350.
20. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance. Investigation of bioavailability and bioequivalence. 111/54/89. European Union, 1991.
21. Schuirmann DJ. A comparison of the two one-sided tests procedure and power approach for assessing equivalence of average bioavailability. J Pharmacokin Biopharmacol 1987; 15: 657-80.
22. Tiseo PJ, Perdomo CA, Freidhoff LT. Concurrent administration of donepezil and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46(Suppl. 1): 25-9.
23. Tiseo PJ, Perdomo CA, Freidhoff LT. Concurrent administration of donepezil and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46(Suppl. 1): 30-4.
24. Tiseo PJ, Foley K, Freidhoff LT. Concurrent administration of donepezil and theophylline: assessment of pharmacokinetic changes following multiple-dose administration in healthy volunteers. Br J Clin Pharmacol 1998; 46(Suppl. 1): 35-9.
25. Tiseo PJ, Perdomo CA, Freidhoff LT. Concurrent administration of donepezil and digoxin: assessment of pharmacokinetic changes. Br J Clin Pharmacol 1998; 46(Suppl. 1): 40-4.
26. Tiseo PJ, Foley K, Freidhoff LT. The effect of multiple doses of donepezil on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol 1998; 46(Suppl. 1): 45-50.
27. BMA. British National Formulary, Number 34. Royal Pharmaceutical Society of Great Britain: September 1997.